Replication Factor C Subunit 4 Plays a Role in Human Breast Cancer Cell Progression.

IF 2.6 4区医学 Q2 GENETICS & HEREDITY

Cancer Genomics & Proteomics Pub Date : 2025-05-01 DOI:10.21873/cgp.20515

Jae Woong Koh, Seon-Joo Park

{"title":"Replication Factor C Subunit 4 Plays a Role in Human Breast Cancer Cell Progression.","authors":"Jae Woong Koh, Seon-Joo Park","doi":"10.21873/cgp.20515","DOIUrl":null,"url":null,"abstract":"Background/aim: Breast cancer is a heterogenous disease characterized by complex molecular pathways that drive its progression. Despite advances in treatment strategies, the need for novel therapeutic targets remains critical. Replication factor C subunit 4 (RFC4) is an important component of the DNA replication machinery and repair pathways. Its precise regulation ensures genomic stability and its dysregulation is implicated in various cancers. However, its oncogenic role in breast cancer is unclear. Therefore, this study aimed to elucidate the biological role of RFC4 in breast cancer.Materials and methods: Breast cancer cell lines MCF7, BT-549, and MDA-MB-231 were transfected with control and RFC4 siRNA to investigate biological functions of RFC4 in breast cancer. Cell proliferation was measured using the MTT and colony formation assays. In addition, cell cycle analysis, migration, and invasion assays were performed on RFC4-depleted breast cancer cells.Results: siRNA-mediated RFC4 knockdown inhibited breast cancer cell proliferation and cell cycle arrest, and reduced cell migration and invasion ability.Conclusion: Our findings highlight the critical role of RFC4 in breast cancer progression. The observed decrease in cell proliferation and clonogenic potential following RFC4 knockdown suggests its potential as a therapeutic target for breast cancer.","PeriodicalId":9516,"journal":{"name":"Cancer Genomics & Proteomics","volume":"22 3","pages":"478-490"},"PeriodicalIF":2.6000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041875/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Genomics & Proteomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/cgp.20515","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Breast cancer is a heterogenous disease characterized by complex molecular pathways that drive its progression. Despite advances in treatment strategies, the need for novel therapeutic targets remains critical. Replication factor C subunit 4 (RFC4) is an important component of the DNA replication machinery and repair pathways. Its precise regulation ensures genomic stability and its dysregulation is implicated in various cancers. However, its oncogenic role in breast cancer is unclear. Therefore, this study aimed to elucidate the biological role of RFC4 in breast cancer.

Materials and methods: Breast cancer cell lines MCF7, BT-549, and MDA-MB-231 were transfected with control and RFC4 siRNA to investigate biological functions of RFC4 in breast cancer. Cell proliferation was measured using the MTT and colony formation assays. In addition, cell cycle analysis, migration, and invasion assays were performed on RFC4-depleted breast cancer cells.

Results: siRNA-mediated RFC4 knockdown inhibited breast cancer cell proliferation and cell cycle arrest, and reduced cell migration and invasion ability.

Conclusion: Our findings highlight the critical role of RFC4 in breast cancer progression. The observed decrease in cell proliferation and clonogenic potential following RFC4 knockdown suggests its potential as a therapeutic target for breast cancer.

查看原文本刊更多论文

复制因子C亚基4在人乳腺癌细胞进展中起作用

背景/目的：乳腺癌是一种异质性疾病，其特点是驱动其进展的复杂分子途径。尽管治疗策略取得了进展，但对新的治疗靶点的需求仍然至关重要。复制因子C亚基4 （RFC4）是DNA复制机制和修复途径的重要组成部分。它的精确调控确保了基因组的稳定性，它的失调与各种癌症有关。然而，它在乳腺癌中的致癌作用尚不清楚。因此，本研究旨在阐明RFC4在乳腺癌中的生物学作用。材料与方法：用对照和RFC4 siRNA转染乳腺癌细胞株MCF7、BT-549和MDA-MB-231，研究RFC4在乳腺癌中的生物学功能。用MTT法和菌落形成法测定细胞增殖。此外，对rfc4缺失的乳腺癌细胞进行了细胞周期分析、迁移和侵袭试验。结果：sirna介导的RFC4敲低抑制乳腺癌细胞增殖和细胞周期阻滞，降低细胞迁移和侵袭能力。结论：我们的研究结果强调了RFC4在乳腺癌进展中的关键作用。RFC4基因敲除后细胞增殖和克隆潜能的降低表明其可能是乳腺癌的治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Genomics & Proteomics ONCOLOGY-GENETICS & HEREDITY

CiteScore

5.00

自引率

8.00%

发文量

期刊介绍： Cancer Genomics & Proteomics (CGP) is an international peer-reviewed journal designed to publish rapidly high quality articles and reviews on the application of genomic and proteomic technology to basic, experimental and clinical cancer research. In this site you may find information concerning the editorial board, editorial policy, issue contents, subscriptions, submission of manuscripts and advertising. The first issue of CGP circulated in January 2004. Cancer Genomics & Proteomics is a journal of the International Institute of Anticancer Research. From January 2013 CGP is converted to an online-only open access journal. Cancer Genomics & Proteomics supports (a) the aims and the research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.